Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Cell Migration through Invadopodia

Cancer Cell Migration through Invadopodia

Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Cancers Originate from Somatic Mutations in a Single Cell

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

Distinctive Features of Adult Stem Cells vs Cancer Stem Cells

A stem cell is an unspecialized cell that can divide without limit as needed and can, under specific conditions, differentiate into specialized cells.
Adult stem cells
Adult stem cells are tissue-specific; hence, they divide to develop the tissue from which they originate. One type of adult stem cell is the epithelial stem cell, which gives rise to the keratinocytes in the multiple layers of epithelial cells in the epidermis of the skin. Adult bone marrow has three distinct types of stem cells:...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

<i>LAMPrey</i>: a standardised method for analysing quantitative LAMP reactions using the inflection cycle threshold.

Biology methods & protocols·2026

Same author

The genome of an enigmatic sea urchin parasite Echinomermella matsi Jones & Hagen, 1987 resolves its place among other invertebrate parasitic nematodes.

G3 (Bethesda, Md.)·2026

Same author

Pressor use and its impact on outcomes in aneurysmal subarachnoid hemorrhage patients with takotsubo cardiomyopathy: a quantitative analysis.

Acta neurochirurgica·2026

Same author

On the path to reference genomes for all biodiversity: laboratory protocols and lessons learned from processing over 2,000 species in the Sanger Tree of Life.

GigaScience·2025

Same author

Tumor-specific CD8 T cell characterization in HR<sup>+</sup> breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis.

Cell reports. Medicine·2025

Same author

T cell memory response to MPXV infection exhibits greater effector function and migratory potential compared to MVA-BN vaccination.

Nature communications·2025

Search research articles

Related Experiment Video

Updated: Feb 12, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Leveraging T cells for cancer immunotherapy.

Adam Bates^1,2, Nicole E Fletcher^1,2, Fei Gao²

¹Radcliffe Department of Medicine, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, Oxfordshire OX3 9DS United Kingdom.

Immunity & Inflammation

|February 11, 2026

Summary

T cells are crucial for fighting cancer, but tumors often evade them. Immunotherapy aims to restore T cell function, though many patients still lack lasting responses. This review explores how T cells combat tumors and how immunotherapies work to overcome evasion.

Keywords:

Adoptive cell transfer Cancer Immune checkpoint blockade Immunotherapy T Cells Vaccination

More Related Videos

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Related Experiment Videos

Last Updated: Feb 12, 2026

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Preparation of Tumor Antigen-loaded Mature Dendritic Cells for Immunotherapy

Published on: August 1, 2013

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Area of Science:

Immunology
Oncology
Cancer Research

Background:

T cells are vital for preventing and controlling tumors.
Tumor progression often results from the evasion or disruption of anti-tumor T cell responses.
Immunotherapy seeks to restore T cell-mediated immunity against cancer.

Purpose of the Study:

To review the role of T cells in tumor control and progression.
To discuss mechanisms of T cell immunity evasion by malignant diseases.
To highlight how various immunotherapies restore anti-tumor T cell responses and address treatment challenges.

Main Methods:

Review of existing literature on T cell function in cancer.
Analysis of mechanisms underlying T cell evasion by tumors.
Examination of soluble, cellular, and vaccine-based immunotherapy strategies.
Discussion of pre-clinical and early-stage clinical developments.

Main Results:

T cell dysfunction is a common mechanism of tumor immune evasion.
Current immunotherapies show promise but often fail to induce durable responses in most patients.
Understanding T cell evasion mechanisms is key to improving immunotherapy efficacy.

Conclusions:

Restoring effective T cell responses is critical for successful cancer immunotherapy.
Addressing specific challenges faced by T cells can enhance therapeutic outcomes.
Emerging strategies hold potential for improving immunotherapy efficacy and patient prognoses.